PMC · DOI:10.1002/ctm2.70366·June 9, 2025
Targeting enabled homolog with daunorubicin inhibits ERK1/2/c‐Fos pathway and suppresses hepatocellular carcinoma progression
Zhi‐Mei Li, Guan Liu, Qing‐Qing Liu, Wei‐Ming You, Ming‐Gao Zhao
Abstract
Linked entities
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Figures3
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsProtein Tyrosine Phosphatases · Cancer Mechanisms and Therapy · PI3K/AKT/mTOR signaling in cancer